Bristol-Myers Squibb Company (BMY) Announces Two- And Three-Year Survival Data For Nivolumab, An Investigational PD-1 Immune Checkpoint Inhibitor, From Advanced Melanoma Cohort Of A Phase 1b Study
5/15/2014 9:29:06 AM
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced updated survival data from the advanced melanoma cohort (n=107) of the expanded Phase 1b dose-ranging study of nivolumab, an investigational PD-1 immune checkpoint inhibitor, administered as a single agent (Study -003). Results showed sustained activity in this heavily pre-treated patient population as defined by two- and three-year survival rates of 48% and 41%, respectively, across dose cohorts. These data, which are based on Kaplan-Meier estimates, will be featured in an oral presentation at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 2 at 3 p.m. CDT (Abstract #9002).
Help employers find you! Check out all the jobs and post your resume.
comments powered by